Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cephalon Reinvention Puts Biologics Front And Center

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Through several acquisitions and alliances completed over the last year, Cephalon has patched together a substantial pipeline of biologic drugs, an area of business the specialty pharma is ramping up as it looks to diversify its portfolio beyond wakefulness and pain.

You may also be interested in...

Cephalon Lands Option To Buy BioAssets For $30 Mil., Eying Anti-TNFs In Sciatica

Cephalon hopes BioAssets' sciatic pain proof-of-concept study for etanercept will pave a development path for its anti-TNF.

Cephalon Option To Buy Biologics Firm Ception Gets The Ball Rolling For 2009, CEO Says

Look for Cephalon to “roll up” more assets this year while the market is good, CEO Baldino says at J.P. Morgan.

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts